# A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Advanced Gastric Cancer.

> **NCT05188209** · PHASE2 · UNKNOWN · sponsor: **Shanghai Miracogen Inc.** · enrollment: 60 (estimated)

## Conditions studied

- Advanced or Metastatic Gastric Cancer
- Advanced or Metastatic Gastroesophageal Junction Carcinoma

## Interventions

- **DRUG:** MRG003

## Key facts

- **NCT ID:** NCT05188209
- **Lead sponsor:** Shanghai Miracogen Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-05-24
- **Primary completion:** 2023-03-21
- **Final completion:** 2023-08-01
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2022-01-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05188209

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05188209, "A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Advanced Gastric Cancer.". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05188209. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*